Welcome to our dedicated page for Xcelerate news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on Xcelerate stock.
Xcelerate Inc. (XCRT) is a diversified healthcare innovator operating across virtual health technology, consumer skincare solutions, and medical equipment licensing. This page provides investors and industry professionals with authoritative updates on the company’s latest developments, strategic partnerships, and regulatory milestones.
Access real-time announcements covering earnings reports, product launches, intellectual property updates, and market expansion initiatives. Our curated news collection ensures you stay informed about XCRT’s advancements in telemedicine platforms, clinically tested skincare formulations like Ceramedx®, and patented surgical technologies.
Bookmark this page for streamlined access to press releases, SEC filings, and analysis of Xcelerate’s cross-sector growth strategies. Regular updates provide insights into how the company integrates engineering innovations with healthcare solutions while maintaining rigorous compliance standards.
Xcelerate (OTCQB:XCRT) has filed two utility patent applications (18/187,352 and 18/189,441) along with corresponding PCT applications (PCT/US2023/015755 and PCT/US2023/016194), building on its prior application from March 24, 2022. The patents focus on surgical tools with targeting guidance and reflect the company's mission to integrate engineering advancements into clinical care. CEO Michael O'Shea highlighted the importance of parallel development and intellectual property protection in their surgical device lines. The company is advancing its In-Tool-Optics prototypes that enhance surgical precision by offering a first-person view. Three product lines are being developed: ITO-Responder for emergency use, ITO-Clinic for hospital environments, and ITO-Infirmary for retrofitting existing tools. This initiative aims to improve efficiency in surgical procedures.
Xcelerate (OTCQB:XCRT) has concluded due diligence and entered into a binding agreement to acquire a controlling interest in ESN Group, Inc. The total transaction value is approximately $350,000 in cash, alongside the issuance of restricted stock, assumption of debt, and employment agreements for essential personnel. The acquisition is anticipated to close by June 30, 2023. This strategic purchase is positioned to provide Xcelerate with an immediate revenue stream and strengthen its portfolio in healthcare and skincare products. CEO Mike O'Shea indicated plans to expand product offerings into mass merchant outlets and government agencies, leveraging ESN's management expertise and industry connections.
Xcelerate, Inc. (OTCQB:XCRT) has signed an agreement with Afya Sasa Africa to implement AI-based healthcare services at Muhimbili National Hospital in Tanzania, the largest hospital in East Africa. This initiative aims to enhance healthcare delivery for Tanzania's 64 million people through advanced technology. The agreement includes multiple revenue streams such as member fees and consultation fees, with anticipated revenue starting in Q4 2023. The project phases include IT assessments and launching a cardiac module, with plans for nationwide expansion pending successful implementation.
FAQ
What is the current stock price of Xcelerate (XCRT)?
What is the market cap of Xcelerate (XCRT)?
